Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein

Author： Wesierska-Gadek Józefa   Schmid Gerald  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.15, Iss.1, 2006-01, pp. : 23-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases

By Jackson Robert C   Barnett Anna L   McClue Steven J   Green Simon R  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 1, 2008-01 ,pp. : 131-143

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors targeting vascular endothelial growth factor receptor kinases and cyclin-dependent kinases

By  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 3, 2005-03 ,pp. : 337-341

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics

By  

Current Medicinal Chemistry, Vol. 7, Iss. 12, 2000-12 ,pp. : 1213-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-dependent kinases and stroke

By Park David S   Wang Fuhu   O’Hare Michael J  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 5, 2001-10 ,pp. : 557-567

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases

By  

Current Pharmaceutical Biotechnology, Vol. 1, Iss. 1, 2000-07 ,pp. : 107-116

Bentham Science Publishers

Access to resources Recommend Favorite